Protein arginine deiminase 4 (PAD4): Current understanding and future therapeutic potential
Department of Biochemistry and Molecular Pharmacology
Animals; Antineoplastic Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Catalysis; Drug Design; *Drug Discovery; Enzyme Inhibitors; Humans; Hydrolases; Immunologic Factors; Isoenzymes; Models, Molecular; Molecular Structure; Multiple Sclerosis; Neoplasms; Protein Conformation; Structure-Activity Relationship
Biochemistry | Enzymes and Coenzymes | Medicinal-Pharmaceutical Chemistry | Therapeutics
The protein arginine deiminases (PADs), and in particular PAD4, have emerged as potential therapeutic targets for the treatment of rheumatoid arthritis (RA). In this review, evidence linking dysregulated PAD activity to the onset and progression of RA is presented, and the potential role of such aberrant activity in other human diseases, such as multiple sclerosis and cancer, is discussed. The known physiological roles of the PADs, particularly PAD4, and current knowledge regarding PAD structure, catalysis and inhibition are also described.
Protein Arginine Deiminase, Rheumatoid Arthritis, Multiple Sclerosis, Cancer, Treatment, Inhibitors
Curr Opin Drug Discov Devel. 2009 Sep;12(5):616-27.
Current opinion in drug discovery and development
Jones JE, Causey CP, Knuckley B, Slack-Noyes JL, Thompson PR. (2009). Protein arginine deiminase 4 (PAD4): Current understanding and future therapeutic potential. Thompson Lab Publications. Retrieved from https://escholarship.umassmed.edu/thompson/62